Ms Shu Chen
- PhD Candidate, UNSW Sydney, Expected in 2023
- Master of Science in Global Health, Duke University, US, 2014
- Bachelor of Arts, Medicine & English, Peking Univerity Health Science Center (Medical School), China, 2012
- Bachelor of Science, Psychology (double major), Peking University, China, 2012
Shu (Melinda) Chen is a third-year Ph.D. candidate, CEPAR and School of Risk and Actuarial Sciences, UNSW (Scientia Scholarships holder), and a senior consultant for the Duke Global Health Institute. She has around a decade of working experience in health policy and system research, and worked closely with international global health funders and partners, such as the Gates Foundation, World Bank, and NIH. She has published over 20 co-authored publications in high-quality peer-reviewed medical journals such as The Lancet Public Health, PLOS Medicine, and BMJ Global Health. She was Associate Director of Research for Infectious Diseases Portfolio, China, FHI 360 and worked at the Global Health Research Center, Duke Kunshan University on health policy and system research before joining UNSW.
- Publications
- Media
- Grants
- Awards
- Research Activities
- Engagement
- Teaching and Supervision
- Deputy director. The Innovation Lab for Vaccine Delivery. Funder: The Bill & Melinda Gates Foundation. 2021-2024. Total funding: 1.9 million USD
- Principal investigator. Landscaping analysis of TB new drugs development in China. Funder: The Bill & Melinda Gates Foundation. 2019-2020. Total funding: 10K USD
- Key team member. Achieving Health SDGs in China: Developing Evidence-based Policy Options for Action. Funder: The Bill & Melinda Gates Foundation. 2016-2018. Total funding: 920K USD
- My research interests include health and long-term care system strengthening, age-related disease prevention (particularly dementia), and infectious disease control and prevention.
- I am passionate about using high-quality evidence to inform policy change to reduce health inequity.
- I am currently working on projects about using an innovative approach to quantify the collective impact of multiple social factors on developing dementia, and vaccine delivery optimization in China.